Panther Biotechnology

Panther Biotechnology, Inc. is an entity focused on acquiring and developing enhanced therapies for the treatment of cancer, autoimmune diseases, and antiviral conditions. The company is currently developing three clinical candidates: TRF-DOX, a combination of transferrin glycoprotein and doxorubicin designed for targeted delivery to reduce severe side effects; Numonafide, a derivative of the extensively studied anticancer drug Amonafide, optimized to eliminate toxic metabolites and minimize side effects; and TDZD-8, a kinase inhibitor targeting cancer stem cells. Panther Biotechnology is continuing its acquisition strategy, focusing on identifying undervalued companies and clinical assets, including projects that have missed clinical endpoints, bringing in scientific and medical personnel capable of conducting trials and extracting value from these assets.